STUART, Fla., May 13, 2025 /PRNewswire/ -- Health In Tech, Inc. (Nasdaq: HIT), an Insurtech platform company backed by third-party AI technology, announced today that the Company's CFO, Julia Qian, has been invited to present at the "2025 Virtual Tech Conference: Discover the Innovations Reshaping Tomorrow," hosted by Maxim Group LLC. The conference will take place from Tuesday, June 3rd to Thursday, June 5th, beginning each day at 9:00 a.m. EDT. Health In Tech is scheduled to present on Tuesday, June 3rd a ...

Core Viewpoint - Danaos Corporation reported strong financial performance for Q1 2025, with total operating revenues of $253.3 million, slightly down from $253.4 million in Q1 2024, while net income decreased to $115.1 million from $150.5 million in the same period last year [2][20][21]. Financial Summary - Operating revenues for container vessels increased by 1.2% to $236.2 million, driven by newbuilding additions, while dry bulk vessel revenues decreased by 14.5% to $17.1 million due to lower charter rates and utilization [21][23]. - Adjusted net income for Q1 2025 was $113.4 million, or $6.04 per diluted share, compared to $140.0 million, or $7.15 per diluted share in Q1 2024 [15][20]. - Adjusted EBITDA decreased by 3.1% to $171.7 million from $177.2 million year-over-year, attributed to increased operating expenses and finance costs [42]. Operational Metrics - The average number of container vessels increased to 73.7 in Q1 2025 from 68.0 in Q1 2024, with fleet utilization for container vessels at 97.2% compared to 97.3% in the previous year [14]. - Dry bulk vessel utilization decreased to 92.4% from 93.6% year-over-year [14]. Recent Developments - The company secured a syndicated loan facility of up to $850 million to finance newbuilding container vessels scheduled for delivery from 2026 to 2028 [11]. - Danaos has a backlog of contracted revenues totaling $3.7 billion, with a charter coverage of 99% for 2025 and 85% for 2026 [10][11]. - A dividend of $0.85 per share was declared for Q1 2025, payable on June 5, 2025 [44]. Market Insights - The dry bulk market has shown modest recovery, but significant growth is contingent on further initiatives in China [9]. - The company is currently focusing on optimizing its existing fleet performance rather than new vessel investments [13]. Environmental Regulations - Proposed IMO regulations on greenhouse gas emissions are seen as insufficient to drive meaningful progress in decarbonization, with limited incentives for using expensive green fuels [11][12].

EMX Royalty Executes an Agreement with Galileo Resources to Acquire a Royalty over the Ferber Polymetallic Project, Nevada, USAMay 13, 2025 4:30 PM EDT | Source: EMX Royalty Corp.Vancouver, British Columbia--(Newsfile Corp. - May 13, 2025) - EMX Royalty Corporation (NYSE American: EMX) (TSXV: EMX) (the "Company" or "EMX") is pleased to announce the execution by its wholly-owned subsidiary Bronco Creek Exploration Inc., of an exploration royalty agreement (the "Agreement") with St. Vincent Mine ...

- Nonhuman primate (NHP) study in hemophilia A demonstrated therapeutically relevant factor VIII (FVIII) activity with durable response through approximately 19 months with an encouraging safety profile - Well capitalized with $226.0 million in cash, cash equivalents and available-for-sale marketable securities as of March 31, 2025 with runway anticipated to support operations into 2027 EMERYVILLE, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company ...

Core Insights - Astrotech Corporation reported a significant increase in revenue for Q3 of fiscal year 2025, reaching $534 thousand compared to $50 thousand in the same quarter of fiscal year 2024, driven by TRACER 1000 shipments, a government grant, and recurring sales [6] - The company has launched four product lines aimed at various markets, including airport security, narcotics detection, and environmental monitoring, indicating a strong growth potential [2][4] - Astrotech's consolidated balance sheet shows a strong cash position with $20.9 million in cash and liquid investments, down from $31.9 million as of June 30, 2024, supporting ongoing R&D and marketing efforts [6] Financial Performance - For the three months ended March 31, 2025, the company reported a gross profit of $237 thousand, a significant increase from $8 thousand in the same period of the previous year [11] - Operating expenses totaled $4.1 million for Q3 2025, compared to $3.5 million in Q3 2024, leading to a loss from operations of $3.9 million [11] - The net loss for Q3 2025 was $3.6 million, compared to a net loss of $3.2 million in Q3 2024, reflecting ongoing investment in product development and market expansion [11] Recent Developments - Astrotech's subsidiary, 1st Detect, was awarded a research and development contract with the Department of Homeland Security to advance the TRACER 1000 for explosives trace detection [6] - The company established a new subsidiary, EN-SCAN, Inc., to focus on environmental testing applications, further diversifying its product offerings [6] - The TRACER 1000 NTD has been configured to screen for synthetic opiates and novel psychoactive substances, enhancing its capabilities in addressing the global drug crisis [6]

All subjects in the NPM-115 cohort had successful insertions of a miniature, ultra long-acting GLP-1 (exenatide) implant in the on-going LIBERATE-1™ study in obese or overweight individuals; top-line results are anticipated in mid-2025 Announced new $3M equity financing together with the previously reported $8.25M equity financing secures financial position into mid-2026 Promising pre-clinical data released for NPM-139 (semaglutide implant) for chronic weight management in obese and overweight patients Comp ...

Multiple Poster Presentations Highlight the Depth and Novelty of MeiraGTx’s Technology Platforms for Gene and Cell TherapyLONDON and NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced the Company will exhibit four poster presentations at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting, which is being held from May 13-17, 2025, in New Orleans, LA. The posters will be avai ...

Malvern, Pa., May 13, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided corporate updates and first quarter 2025 financial results. The first quarter was largely dedicated to the initiation of a pivotal Phase 3 clinical trial in early AD, with the first participants entering the study on ...

Amid a sudden rebound back into what feels like bull market territory, investors should continue to be very mindful of stretching valuations. One of the major reasons that the markets fell so sharply following tariff announcementsWith combined experience of covering technology companies on Wall Street and working in Silicon Valley, and serving as an outside adviser to several seed-round startups, Gary Alexander has exposure to many of the themes shaping the industry today. He has been a regular contributor ...

Presented new amezalpat mechanism-of-action data reinforcing its potential as a novel cancer treatment at the 2025 AACR Annual MeetingGranted Orphan Drug designation by FDA for TPST-1495 for the treatment of familial adenomatous polyposis (FAP)Received FDA “Study May Proceed” letter for Phase 2 trial of TPST-1495 for the treatment of FAPGranted both Orphan Drug & Fast Track designations by FDA for Amezalpat (TPST-1120) for the treatment of patients with hepatocellular carcinoma (HCC) BRISBANE, Calif., May 1 ...